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Summary
Epidermal growth factor receptor (EGFR) exists in the nucleus of highly proliferative cells where it functions as a transcrip-
tion factor. Although EGFR has transactivational activity, it lacks a DNA binding domain and, therefore, may require a DNA
binding transcription cofactor for its transcriptional function. Here, we report that EGFR physically interacts with signal
transducers and activators of transcription 3 (STAT3) in the nucleus, leading to transcriptional activation of inducible nitric
oxide synthase (iNOS). In breast carcinomas, nuclear EGFR positively correlates with iNOS. This study describes a mode
of transcriptional control involving cooperated efforts of STAT3 and nuclear EGFR. Our work suggests that the deregulated
iNOS/NO pathway may partly contribute to the malignant biology of tumor cells with high levels of nuclear EGFR and
STAT3.S I G N I F I C A N C E
Although the nuclear existence of EGFR has been documented for more than a decade, our understanding of the physiological
contribution of the nuclear EGFR pathway to the biology of cancer cells remains very limited. Here, we report a transcriptional
mechanism by which gene expression can be directly regulated by two oncogenic products, EGFR and STAT3. The transcriptional
complex that consists of nuclear EGFR and STAT3 may potentially represent a class of transcription factors that functionally interact
at both cytoplasmic and nuclear levels, resulting in a direct transduction of extracellular signals from the cell surface to the nucleus.
Thus, the findings reported in this study significantly advance our understanding of the EGFR pathway that occurs in the cell nucleus.Introduction
EGFR/ErbB1 belongs to the ErbB family of receptor tyrosine
kinases (RTKs) (Cohen et al., 1982a). Overexpression and/or
increased activity of EGFR are key characteristics of human
tumors and are frequently linked to more aggressive tumor be-
haviors, including increased proliferation, metastasis, and ther-
apeutic resistance (Craven et al., 2003). As such, EGFR is con-
sidered an outstanding therapeutic target for human cancers
(Arteaga, 2003; Mendelsohn and Baselga, 2003).
Our understanding of EGFR-overexpressing tumors remains
incomplete, which is evidenced by several recent reports re-
vealing that, in addition to the level of expression, somatic mu-
tations of EGFR played a critical role in the therapeutic re-
sponse in non-small-cell lung cancer (NSCLC) patients (Lynch
et al., 2004; Paez et al., 2004). More recently, we found an
inverse correlation between nuclear EGFR and overall survival
in patients with breast cancer, suggesting a prognostic value of
nuclear EGFR (Lo et al., 2005). Consequently, a more thorough
understanding of the EGFR signaling pathway will facilitate the
future success of clinically used anti-EGFR agents and the de-
velopment of novel therapies that target the EGFR pathway.
Emerging evidence indicates a mode of EGF signaling in
which growth factor signals can be transmitted, via EGFR
nuclear transport, directly from the cytoplasmic membrane toCANCER CELL : JUNE 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INC.the transcriptional targets in the nucleus (Bourguignon et al.,
2002; Lin et al., 2001; Lo et al., 2005; Marti et al., 1991; Marti
and Hug, 1995; Wells and Marti, 2002). This direct pathway is
distinct from the traditional ErbB pathway that requires activa-
tion of signaling cascades, such as those involve phospholi-
pase C-γ, Ras, and phosphatidylinositol-3 kinase (Anderson et
al., 1990; Cohen et al., 1982b; Hu et al., 1992). In addition to
EGFR, all other receptors in the ErbB family have also been
detected in the cell nucleus (Lin et al., 2001; Marti and Hug,
1995; Ni et al., 2001; Offterdinger et al., 2002; Wang et al.,
2004; Xie and Hung, 1994). Importantly, nuclear EGFR and
HER-2 have been shown to be involved in the transcription of
cyclin D1 and cyclooxygenase-2 (COX-2) genes, respectively
(Lin et al., 2001; Wang et al., 2004).
Other RTKs also translocate into the nucleus, such as the
fibroblast growth factor receptor, TrkA/nerve growth factor re-
ceptor, insulin receptor, and type I TGFβ receptor (Chan et al.,
2003; Maher, 1996; Podlecki et al., 1987; Raabe et al., 2004;
Rakowicz-Szulczynska et al., 1988; Reilly and Maher, 2001;
Zhang et al., 2003; Zwaagstra et al., 2000). Inflammatory cyto-
kines, such as interleukin-1 (IL-1), IL-5, and interferon-γ (IFN-γ),
and their receptors, also undergo nuclear translocalization;
however, their function in the nuclear compartment is largely
unknown (Bader and Weitzerbin, 1994; Curtis et al., 1990;
Grasl-Kraupp et al., 2002; Jans et al., 1997; Jans and Hassan,DOI 10.1016/j.ccr.2005.05.007 575
A R T I C L E1998; Larkin et al., 2000; Subramaniam and Johnson, 2002;
Zwaagstra et al., 2000). While the physiological and pathologi-
cal consequences of the nuclear presence of cell-surface re-
ceptors remain unclear, a role of nuclear EGFR in tumor ag-
gressiveness and poor clinical outcome is suggested (Lo et
al., 2005).
Several questions remained unanswered regarding the nuclear
function of ErbB RTKs. For example, additional unidentified
transcriptional targets may exist. It is also unknown how these
receptors activate gene transcription, as they lack a putative
DNA binding domain. Nevertheless, the EGFR complex specifi-
cally recognizes AT-rich sequences, designated ATRSs (Lin et
al., 2001). The nuclear EGFR complex associates with the
ATRSs within the cyclin D1 promoter and activates its gene
promoter (Lin et al., 2001). Nuclear HER-2 binds to the HER-
2-associated sequence (HAS) in the COX-2 promoter, resulting
in its transcriptional activation (Wang et al., 2004). The carboxyl
terminus of EGFR, HER-2, rat p185/neu, and ErbB4 contains
transactivational activity (Lin et al., 2001; Ni et al., 2001; Wang
et al., 2004; Xie and Hung, 1994). Together, these observations
suggest the possible existence of transcription cofactors with
DNA binding ability that cooperate with nuclear EGFR to regu-
late gene expression.
STAT3 is a DNA binding transcription factor that is activated
by cytokines and growth factors, and, upon activation, elicits
its function by regulating gene expression (Darnell et al., 1994;
Fu, 1999). STAT3 becomes phosphorylated at Y705 and acti-
vated (Park et al., 1996) by cell-surface EGFR following its as-
sociation with the C terminus of EGFR (Coffer and Kruijer,
1995; Shao et al., 2003). Whether such association occurs in
the nuclear compartment, however, has not been investigated.
Interestingly, a recent report demonstrated that both EGF and
activated STAT3 translocate to the perinuclear region via endo-
somes (Bild et al., 2002), implying that EGFR and STAT3 may
interact in cellular locations other than the plasma membrane.
STAT3 activates the transcription of genes involved in cell-
cycle progression and antiapoptosis (Barre et al., 2003; Bow-
man et al., 2001; Karni et al., 1999; Shirogane et al., 1999;
Sinibaldi et al., 2000; Yang et al., 2003). More recently, consti-
tutively active STAT3 was shown to activate vascular endothe-
lial growth factor (VEGF), leading to increased angiogenesis
and tumor metastasis (Niu et al., 2002; Wei et al., 2003). Con-
sequently, STAT3 has a major role in oncogenesis (Bromberg
et al., 1999), angiogenesis (Niu et al., 2002), and tumor metas-
tasis (Wei et al., 2003) and is thus a favorable target for cancer
drug development (Turkson and Jove, 2000).
EGF has been shown to elevate nitric oxide (NO) production
(Cianchi et al., 2004; Fantappie et al., 2002). The gaseous sec-
ond messenger, NO, is frequently elevated in cancerous cells,
and such elevation has been linked to tumor growth and me-
tastasis (Jenkins et al., 1995; Lala and Orucevic, 1998). In-
creased expression of iNOS, a potent NO-producing enzyme,
is another key characteristic of many human malignancies, in-
cluding breast cancer (Ekmekcioglu et al., 2000; Vakkala et al.,
2000). Overexpression of iNOS is significantly associated with
tumor growth and angiogenesis (Cianchi et al., 2003; Vakkala
et al., 2000). For these reasons, iNOS is considered an attrac-
tive target for both chemoprevention and chemotherapy (Jade-
ski and Lala, 1999; Rao et al., 2002). Although overexpression
of both EGFR and iNOS is commonly observed in human can-
cers, a direct and consistent link between the EGFR and iNOS/576NO pathways has not been established. For example, EGF in-
duced expression of iNOS in normal astrocytes (Liu and Neu-
feld, 2003) and in head and neck squamous cell carcinomas
(Gallo et al., 2002). However, such regulation was not found in
other cellular systems (Salzman et al., 1996; Wang et al., 1999).
In an attempt to search for a nuclear protein that binds to
EGFR, we found that nuclear EGFR physically and functionally
interacts with STAT3, leading to activation of the iNOS gene
whose promoter contains regulatory elements for both mole-
cules. Furthermore, in a cohort of 111 breast carcinomas, we
found an inverse correlation between iNOS expression and
overall patient survival. Together, these findings describe a new
mode of transcription machinery that involves physical and
functional interaction between STAT3 and its associating re-
ceptor, EGFR. Our work also implies that deregulated iNOS
expression may, in part, contribute to the malignant biology in
tumors with increased nuclear EGFR and STAT3.
Results
Nuclear interaction of EGFR and STAT3
Since it is well established that transmembrane EGFR interacts
with and activates STAT3, resulting in STAT3 nuclear translocal-
ization and gene activation (Coffer and Kruijer, 1995; Park et
al., 1996), and EGFR has been shown to be located in the nu-
cleus and to associate with transcriptional activity (Lin et al.,
2001; Lo et al., 2005), we asked whether STAT3 and EGFR
might interact with each other to exert their transcriptional
function in the nucleus. To this end, we found EGFR coloca-
lized and physically associated with STAT3 in the nucleus (Fig-
ure 1). The association between EGFR and STAT3 in the
nuclear compartment was first demonstrated by coimmuno-
precipitation/Western blot (coIP/WB) analyses in EGFR-overex-
pressing A431 cells (Figure 1A). The level of nuclear EGFR/
STAT3 complex was significantly enhanced by 30 min of EGF
treatment (Figure 1A, left). As a positive control, Figure 1B (left)
shows that cytoplasmic EGFR interacted with STAT3, and the
interaction was enhanced following 30 min of EGF treatment.
Lack of PARP in the cytosolic fraction indicates that it is free
of nuclear contamination (Figure 1B, right). In the immunofluo-
rescent microscopy/deconvolution analyses (Figure 1C), colo-
calization of EGFR (red) and STAT3 (green) occurred near the
cell surface 10 min after EGF stimulation (yellow signals). After
30 min of EGF treatment, EGFR and STAT3 colocalized pre-
dominantly in the nucleus. In these studies, approximately 20–
30 cells were analyzed for each treatment and the majority
(70%–75%) of them behaved similarly. A few cells representa-
tive of those examined are shown in Figure 1C.
To further ensure that nuclear interaction occurs between
EGFR and STAT3, we used electron microscopy (EM) using an-
other EGFR-overexpressing cell line, MDA-MB-468 human
breast carcinoma cells (Figures 1D and 1E). As shown in Figure
1D, inset a, nuclear EGFR (solid arrows) interacts with STAT3
(dashed arrows). The observed colocalization pattern resem-
bles patterns previously reported in which 15 nm (EGFR) and
5 nm (STAT3) gold particles were detected in close proximity
(Violot et al., 2003). Also noticeable is that a portion of nuclear
EGFR did not colocalize with nuclear STAT3 (inset b) and vice-
versa (inset c). This suggests that both EGFR and STAT3 may
remain in an unbound form or associate with other nuclear pro-
teins. In contrast, negative controls shown in Figure 1E did notCANCER CELL : JUNE 2005
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Tumor cells were analyzed for colocalization of EGFR and STAT3. Cells were serum starved for 24 hr prior to EGF treatment.
A and B: Co-IP/WB analyses. A431 cells without (−) or with 30 min EGF (+) treatment were harvested and fractionated into nuclear (A) and cytosolic (B)
fractions. Co-IP/WB (left) or WB (right) was carried out using indicated antibodies.
C: Immunofluorescent microscopy/deconvolution analyses. A431 cells were immunostained for EGFR (red) and for STAT3 (green), and their nuclei were
stained with DAPI (blue). Arrows indicate colocalization of EGFR and STAT3 (yellow).
D and E: EM analysis. (D) EGF-stimulated MDA-MB-468 cells were stained for EGFR (large particles, solid arrows) and for STAT3 (small particles, dashed
arrows). Insets a, b, and c are higher-resolution images showing the EGFR/STAT3 complex, EGFR, and STAT3, respectively. (E) Negative controls using EGFR
Ab only (top) or secondary Ab only (bottom). Scale bar represents 100 nm. Cy, cytosol; NM, nuclear membrane; Nu, nucleus.CANCER CELL : JUNE 2005 577
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As expected, we also observed, using EM analysis, EGFR/
STAT3 interaction near the plasma membrane and the cyto-
plasm (See Figures S1A and S1B in the Supplemental Data
available with this article online). We also observed the exis-
tence of nuclear STAT3 prior to EGF treatment and the level
enhanced by EGF (Figure S1C). This observation is consistent
with previous reports showing that STAT3 is constitutively acti-
vated in MDA-MB-468 cells (Garcia et al., 2001). EGF-activated
EGFR nuclear transport and nuclear interaction of EGFR and
STAT3 were further detected in nontransformed immortalized
HaCaT human keratinocytes that express both proteins (Figure
S1D) (Sriuranpong et al., 2003). Together, these findings dem-
onstrate a nuclear interaction of EGFR and STAT3 that has not
been described previously.
In vivo binding of nuclear EGFR and STAT3
to the iNOS promoter
The identification of a nuclear interaction between EGFR and
STAT3 prompted us to search for candidate target genes that
are regulated by the nuclear EGFR/STAT3 complex. Since both
are known to bind to specific DNA sequences to activate tran-
scription, we performed both database (TFSEARCH, http://
www.cbrc.jp/research/db/TFSEARCH) and literature searches
to identify cancer-related genes that contain binding sites for
both EGFR and STAT3. We found five gene promoters that con-
tain both binding sites: namely, iNOS, c-fos, cyclin D1, human
telomerase reverse transcriptase (hTERT), and VEGF. VEGF
and c-fos can be up-regulated by STAT3 (Niu et al., 2002; Wei
et al., 2003; Yang et al., 2003). The promoter of hTERT is acti-
vated by EGF via Ets (Maida et al., 2002). It should be noted
that the functionality of the two ATRS motifs in the cyclin D1
gene promoter (−74 to −70 and −31 to −27) and the STAT3
binding sites in the promoters of the c-fos (−348 to −339) and
VEGF (−842 to −849) genes have been previously charac-
terized (Lin et al., 2001; Niu et al., 2002; Wei et al., 2003; Yang
et al., 2003). We selected promoters of cyclin D1, c-fos, and
iNOS for binding analysis. Among them, the EGFR binding site
(ATRS) of the cyclin D1 promoter and STAT3 binding site of the
c-fos promoter have been shown experimentally (Lin et al.,
2001; Yang et al., 2003). The other ATRS and STAT3 sites in
these three promoters are identified on the basis of sequence
homology predicted from the computer-based analysis.
To examine whether these genes are targets for both nuclear
EGFR and STAT3, we initially performed an in vivo binding as-
say, chromatin immunoprecipitation (ChIP). As summarized in
Figure 2A, we observed significant and specific EGF-induced
binding of both nuclear EGFR and STAT3 to the iNOS promoter.
Consistently, quantitative real-time PCR confirmed in vivo EGF-
activated binding of nuclear EGFR and STAT3 to the iNOS pro-
moter by 3.3 ± 1.8-fold and 3.6 ± 0.5-fold, respectively. For
the cyclin D1 promoter (Figure 2B), we observed EGF-activated
binding of nuclear EGFR, as previously reported (Lin et al.,
2001). Nuclear STAT3, however, binds to the cyclin D1 pro-
moter independently of EGF stimulation (Figure 2B). Support-
ing the previous finding that STAT3 regulates the c-fos pro-
moter via its STAT3 binding site (−348 to −339), Figure 2B
shows that STAT3 binds to the c-fos promoter as expected,
and the binding is significantly enhanced by EGF. Interestingly,
we also found the nuclear EGFR to associate with the c-fos
promoter following EGF activation (Figure 2B). These observa-578Figure 2. ChIP analysis of EGFR/STAT3 complex binding at promoters of
iNOS, cyclin D1, and c-fos in vivo
MDA-MB-468 cells were serum starved for 24 hr then left without (−) or stim-
ulated with EGF (+) for 30 min.
A and B: Association of EGFR and STAT3 with promoters of iNOS (A), cyclin
D1, and c-fos (B) detected using indicated antibodies.
C: Association of EGFR/STAT3 complex with the iNOS promoter was de-
tected using sequential IP. Following the first IP using EGFR Ab, EGFR:chro-
matin complex was eluted and subjected to second IP using Abs for STAT3
or EGF. The IP efficiency of the EGF Ab was tested by IP/WB using whole
cell lysates (right).tions were further confirmed by quantitative real-time PCR
analysis (data not shown). Together, these data demonstrate
that both nuclear EGFR and STAT3 in vivo bind to all three
promoters and that EGF enhanced such binding, except for
that of STAT3 to the cyclin D1 promoter.
In vivo binding of nuclear EGFR/STAT3 complex
to the iNOS promoter
Next, we examined whether the nuclear EGFR/STAT3 complex
associates with the iNOS, cyclin D1, and c-fos gene promoters,
using sequential ChIP analyses. This investigation is particu-
larly important given that EGFR forms a complex with STAT3
in the nuclear compartment (Figure 1). In these studies, we im-
munoprecipitated nuclear EGFR-associated chromatins with
EGFR Ab, eluted the protein:chromatin complex, and then re-CANCER CELL : JUNE 2005
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Ab. Simultaneously, chromatins were reimmunoprecipitated
with EGF Ab to determine whether nuclear EGFR remains
bound to EGF while associating with the promoters. The se-
quential ChIP assay suggests that the nuclear EGFR/STAT3
complex in vivo binds to the iNOS promoter, but not that of the
cyclin D1 or c-fos genes (Figure 2C, left). In contrast, in the
ChIP experimental conditions, nuclear EGFR did not maintain
its association with its ligand, EGF, when interacting with the
promoters (Figure 2C, left), although the EGF Ab used for re-
IP was effective in pulling down both EGF and EGFR, as indi-
cated by coIP/WB analysis (right).
EGF/EGFR enhances iNOS gene expression
Detection of the EGFR/STAT3 complex interacting with the
iNOS promoter prompted us to address whether EGF may reg-
ulate iNOS expression. Using reverse transcriptase-polymer-
ase chain reaction (RT-PCR), we observed that EGF increased
the iNOS mRNA level by w7-fold in MDA-MB-468 cells (Figure
3A). Using quantitative real-time PCR, we observed an immedi-
ate early activation of iNOS transcription at 1 hr after EGF treat-
ment, and the level increased to approximately 5-fold at 6 hr
(lower panel, Figure 3A). The protein synthesis inhibitor, cyclo-
heximide, did not significantly affect the EGF effect (data not
shown). Consistently, WB analysis also shows an approxi-
mately 7.5-fold increase in iNOS protein expression after EGF
treatment (Figure 3B). As a positive control for EGF responsive-
ness, we also analyzed the ability of EGF to alter VEGF gene
expression, as it has been shown that activated STAT3 en-
hanced its gene activity (Niu et al., 2002). As expected, EGF
treatment significantly increased levels of both the transcripts
and the proteins of VEGF. Furthermore, we observed an in-
crease of approximately 2.4-fold in endogenous NO after 24 hr
of EGF treatment (Figure 3C). The degree of NO-induction by
EGF is comparable to previously reported 3- to 3.5-fold in co-
lon and liver cancer cells (Cianchi et al., 2004; Fantappie et al.,
2002). Thus, EGF/EGFR, indeed, induces iNOS gene ex-
pression.Figure 3. EGF/EGFR enhances iNOS gene ex-
pression
A and B: The expression of iNOS and VEGF
genes in MDA-MB-468 cells without and with
EGF for 6 hr was examined using (A) RT-PCR and
(B) WB analyses. Lower panel in A: Quantitative
real-time PCR method. The levels of iNOS tran-
scripts were normalized against those of
GAPDH, and all numbers (mean ± SD) were cal-
culated from three independent experiments.
C: EGF enhances NO production. Levels of total
NO (nitrite and nitrate) were determined in
MDA-MB-468 cells without (−) or with 24 hr EGF
treatment (+). Means ± SD (error bars) were de-
rived from three independent experiments.CANCER CELL : JUNE 2005Characterization of iNOS gene promoter for EGF
responsiveness
We further characterized the elements responsible for EGFR/
STAT3 regulation in the iNOS promoter by examining re-
sponses to EGF of luciferase reporters driven by various dele-
tion mutants of a 7.2 kb iNOS promoter. As indicated in Figure
4A, we observed the highest EGF responsiveness from the 0.3
kb iNOS promoter, and this construct was used in subsequent
reporter studies.
Next, we aimed to identify the response elements in the
iNOS gene promoter recognized by nuclear EGFR and STAT3.
The iNOS promoter contains two clusters of putative ATRS/
STAT3 sites that are highly homologous to the consensus se-
quences (Figure 4B). EGF enhanced the binding of nuclear
EGFR and STAT3 to both NOS-1 and NOS-2 probes, with more
profound stimulation for the NOS-1 probe (Figure 4B, left). As
positive binding controls, nuclear EGFR and STAT3 bind to the
cyclin D1 ATRS (CYD-ATRS) and a functional STAT3 binding
site (APRE, acute-phase response element) known to bind to
the STAT3/APR factor (Wegenka et al., 1993; Yu et al., 1995),
respectively, following EGF stimulation (Figure 4B, mid-panel).
Using an electrophoresis mobility shift assay (EMSA), we found
significant EGF-activated binding of nuclear protein to both
NOS-1 and NOS-2 (left, Figure 4C). Analysis of the compo-
nents binding to the iNOS probes, via EMSA/WB, revealed the
high-molecular-weight signals (arrowed) to contain both EGFR
and STAT3 (left, Figure 4C). When the Abs for EGFR and STAT3
were included in the binding reactions, we observed disap-
pearance of the high molecular band, marked by arrows (right,
Figure 4C), indicating the interference of protein-DNA com-
plexes by specific Abs recognizing EGFR and STAT3 or indicat-
ing the inability of the large EGFR/STAT3/Ab complex to enter
the gels. Similar band disappearance was observed when
binding reactions included Abs raised against the N- and
C-terminal EGFR regions, but not the β-actin Ab (Figure S2).
Collectively, these findings suggest that both nuclear EGFR
and STAT3 interacted with the NOS-1 and NOS-2 regions in
the iNOS promoter.
To further identify the critical nucleotides within the NOS-1
and NOS-2 regions that are required for the binding to nuclear579
A R T I C L EFigure 4. Characterization of iNOS gene promoter for EGF responsiveness
A: Activities of the 7.2 kb iNOS promoter and its deletion mutants were analyzed using a luciferase reporter system in MDA-MB-468 cells. N-box: NRE at
−6749 to −6739. NK/ST-box: NF-kB/STAT1 elements at −5.8 kb. ST-box: STAT1 binding site at −5.2 kb.
B: EGF stimulates binding of nuclear EGFR and STAT3 to the iNOS promoter. Top panel: sequences of NOS-1 and NOS-2. Solid-line box, ATRS; dashed-line
box, STAT3 binding site. Biotinylated oligonucleotides as indicated were used in the binding assay (left and middle panels). Levels of EGFR, STAT3, and
histone in A431 nuclear lysates were examined using WB analysis (right).
C: EGF-activated binding of nuclear EGFR and STAT3 to the iNOS promoter. Left: EMSA was performed using 32P-labeled probes and detected using
autoradiography, whereas EMSA/WB was performed using an unlabeled probe and detected using indicated Abs; these reactions were run on the same
gel. Right: EMSA analyses performed in the presence of indicated Abs. The arrow marks the band containing both nuclear EGFR and STAT3.
D, E, and F: Nucleotides critical for NOS-1 and NOS-2 binding the EGFR/STAT3 complex. (D, left) Sequences of NOS-1 and NOS-2 and their mutants; mutated
nucleotides are shown in bold, and critical nucleotides are shown in italicized bold. (D–F) EMSA competition experiments carried out without (−) or with
200-fold molar excess of indicated unlabeled probes. Arrows mark the EGFR/STAT3-containing complex.
G: Transcription activity of mutant iNOS promoters. Luciferase activity from MDA-MB-468 cells transfected with indicated reporter plasmids without (−) or
with (+) EGF treatment was determined the means ± SD (error bars) were derived from three independent experiments.580 CANCER CELL : JUNE 2005
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tant oligonucleotides were generated (Figure 4D). The unla-
beled M-1 mutant failed to compete for EGFR/STAT3 binding,
indicating its inability to interact with nuclear EGFR/STAT3 and
the functional importance of the two nucleotides TT (−137 and
−136) for NOS-1 (Figures 4D and 4E). In contrast, unlabeled
NOS-1 and NOS-2 probes effectively outcompeted the binding
signal, indicating binding specificity and suggesting that the
same DNA binding protein was involved in the binding to both
NOS-1 and NOS-2 (Figures 4D and 4E). Moreover, the M-2 mu-
tant remains the function of wild-type NOS-2, indicating that
the two nucleotides TT (−73 and −72) are not important for
the functionality of NOS-2. Interestingly, neither cyclin D1 ATRS
(CYD-ATRS) nor the STAT3 binding site, APRE, was able to
outcompete the binding signals, suggesting that the complex
structural requirement may lie within the promoter element that
is specific for EGFR/STAT3 recognition (Figures 4D and 4E).
As the M-2 mutant retains its binding function as the wild-
type NOS-2, we further designed and tested three additional
mutants: M-3, M-4, and M-5 (Figure 4D and Table S2). As indi-
cated by Figure 4F, the binding of the nuclear EGFR/STAT3
complex to the NOS-2 probe was outcompeted by the M-3
mutant, but not by the M-4 and M-5 mutants, indicating that
the nucleotides AAA at positions -65 to -63 are critical bases
for NOS-2 functionality. Using reporters containing 0.3-kb
iNOS promoters mutated at M-1or M-4 as well as both M-1
and M-4 positions, we further examined the functionality of the
EGFR/STAT3 binding elements in the iNOS promoter. We found
double mutations at both M-1 and M-4 positions significantly
reduced the activity of the iNOS promoter (Figure 4G). Interest-
ingly, the iNOS promoter with mutations at either M-1 or M-4,
within NOS-1 and NOS-2 regions respectively, did not signifi-
cantly alter promoter activity, suggesting that one cluster of
wild-type EGFR/STAT3 elements is sufficient for EGF-respon-
siveness. Taken together, these analyses indicate the impor-
tance of EGFR/STAT3 elements within both NOS-1 and NOS-2
regions in EGF responsiveness and in the basal activity of the
iNOS promoter.
EGFR and STAT3 expression/activity are important
for EGF-induced iNOS promoter activity
In addition to STATs, EGF can activate multiple signaling path-
ways such as Ras/MAPK and PI3K/Akt. We then asked
whether EGF activates the iNOS promoter via the EGFR/STAT3
module and whether nuclear EGFR is important during such
activation. AG490 (Jak2/STAT kinase inhibitor) and PD158780
and AG1478 (EGFR kinase inhibitors) inhibited the phosphory-
lation and activity of their respective targets as expected (Fig-
ure 5A, right, and Figure S3). AG490 reduced EGF-induced
iNOS promoter activity by 95%, whereas PD158780 and
AG1478 reduced it by 45%–74% (Figure 5A). Consistently, 1
hr pretreatment of AG490, AG1478, AG490/1478, and gefitinib
(Iressa) inhibited NO production, with the combination of
AG490 and AG1478 producing the highest rate of suppression
(Figure 5B). The reduction of NO synthesis by gefitinib was not
due to cell death, as the MTT cell proliferation assay showed
only approximately 10% cell-kill after 24 hr treatment of 2.5
M gefitinib (data not shown). It was also evident that gefitinib
pretreatments abolished EGF-induced EGFR activation/phos-
phorylation and, to a lesser degree, that of STAT3 while theCANCER CELL : JUNE 2005total endogenous levels of EGFR and STAT3 remained con-
stant (Figure 5C).
To determine whether EGF-induced iNOS expression re-
quires nuclear EGFR. We generated an EGFR mutant that is
defective in nuclear entry but retains its cell-surface location/
functions by mutating a putative nuclear localization signal
(pNLS; 645RRR647 to AAA) located within the juxtamembrane
domain (Lin et al., 2001; Waugh and Hsuan, 2001). A similar
NLS is also found in the juxtamembrane domain of HER-2 and
ErbB4, the deletion/mutation of which rendered these mole-
cules unable to enter the cell nucleus (Wang et al., 2004; Wil-
liams et al., 2004). Three stable lines were then generated from
the parental EGFR-null CHO cells and designated CHO-NEO,
CHO-EGFR, and CHO-EGFR-pNLS to express the parental
vector, wild-type EGFR, and EGFR-pNLS mutant, respectively.
The EGFR mutant in CHO-EGFR-pNLS cells is not present in
the nucleus (Figure 5D, left) and therefore did not interact with
nuclear STAT3 (Figure 5D; right), whereas significant amounts
of EGFR were contained in both nuclear and nonnuclear frac-
tions of CHO-EGFR cells, and the interaction between nuclear
EGFR and STAT3 was readily detectable (Figure 5D; right). In
contrast to enhanced iNOS promoter activity and iNOS expres-
sion in CHO-EGFR cells, EGF did not increase iNOS promoter
activity or iNOS expression in CHO-NEO and CHO-EGFR-
pNLS cells (Figure 5E).
Additionally, we found that the wild-type EGFR and the pNLS
mutant interacted with STAT3 to a similar degree in the whole-
cell lysates, as shown by Figure 5D (middle), indicating that the
pNLS mutation does not affect the ability of EGFR to interact
with STAT3. We also detected nuclear STAT3 in all three CHO
lines, suggesting that the intact STAT3 pathway alone is not
sufficient for activating the iNOS promoter following EGF stim-
ulation and that STAT3 nuclear import can occur independently
of EGFR subcellular location (Figure 5D, left). Moreover, the
EGFR-pNLS mutant retains its cell-surface function (Figure 5F,
left) that transduces the classical EGFR-Ras-ERK pathway and
activates the elk-target promoter (Rao and Reddy, 1993). In ad-
dition, the EGFR-pNLS mutant retains its cell-surface localiza-
tion (data not shown) and undergoes EGF-induced autophos-
phorylation at Y1045 (Figure 5F, right). Together, these data
indicate that the pNLS region within EGFR is required for its
nuclear import and that nuclear EGFR is important for the acti-
vation of the iNOS promoter and subsequent NO production.
We next attempted to demonstrate the requirement of STAT3
in EGF-mediated iNOS gene activation, as EGF/EGFR has
been shown to activate, in addition to STAT3, other members
of the STAT family of proteins, such as STAT1 and STAT5. Fig-
ure 5G shows that a dominant-negative STAT3 (STAT3-DN) mu-
tant, which carries the mutation Y705F (Nakajima et al., 1996),
reduced the ability of EGF to activate the iNOS promoter. In
addition, iNOS promoter activity was increased in cells ex-
pressing a constitutively active STAT3 (Stat3-C) (Bromberg et
al., 1999) with and without EGF. Furthermore, STAT3 siRNA,
which reduced the protein level of STAT3 but not of STAT1,
suppressed the 0.3 kb iNOS promoter activity by approxi-
mately 75% in CHO-EGFR cells and by 50% in CHO-EGFR-
pNLS cells transiently expressing wild-type EGFR (Figure 5H).
Consistently, STAT3 siRNA, but not nonspecific (NS) siRNA, re-
duced iNOS expression (Figure 5H, right). Together, these data
indicate that STAT3 expression/activity is important for the acti-
vation of the iNOS gene promoter.581
A R T I C L EFigure 5. EGFR and STAT3 are important for EGF-induced iNOS promoter activity
Means ± SD (error bars) were derived from at least three independent experiments.
A: Reduction of iNOS promoter activity by inhibitors to Jak2 and EGFR. Luciferase activity of MDA-MB-468 cells transfected with piNOS(0.3)Luc and then
treated with indicated inhibitors for 30 min prior to 4 hr EGF stimulation was determined and compared to that of cells not treated with inhibitor. Inhibition
of phosphorylation of EGFR or of STAT3 in cells treated with indicated inhibitors for 1 hr prior to 30 min EGF stimulation was determined using WB (right).
B: Reduction of EGF-induced NO synthesis by 10 M AG490, 10 M AG1478, and 2.5 M gefitinib. MDA-MB-468 cells were pre-treated with indicated
inhibitors for 1 hr prior to 24 hr EGF stimulation. Total nitrate/nitrite content (pmol/g protein) was determined.
C: Gefitinib effectively inhibits EGFR activation/autophosphorylation. MDA-MB-468 cells were treated without and with gefitinib for 1 hr prior to 30 min
EGF stimulation.
D: EGFR-pNLS mutant fails to enter the nucleus, but retains a functional STAT3 signaling pathway. Left: Expression of EGFR and EGFR-pNLS. Middle: EGFR
and EGFR-pNLS bind to STAT3 in whole-cell lysate. Right: EGFR binds STAT3 in nuclear lysate.
E: Nuclear EGFR is important for EGF-induced iNOS gene activity. The EGF-induced iNOS promoter activity was determined by either reporter assay (left)
or expression of iNOS (right) in indicated CHO cell lines.
F: EGFR-pNLS mutant activates elk-targeted promoter (left) and undergoes autophosphorylation in response to EGF (right).
G: STAT3 activation is important for iNOS promoter activity. Luciferase activity in Hela cells transfected with piNOS(0.3)Luc alone or together with plasmids
expressing STAT3-DN or Stat3-C was determined.
H: STAT3 expression is important for iNOS promoter activity. Luciferase activity (left) and levels of indicated proteins (right) in cells transfected with piNOS(0.3)-
Luc alone or with indicated siRNA. Left: Luciferase activity derived from piNOS(0.3)Luc. Right: WB analysis.582 CANCER CELL : JUNE 2005
A R T I C L ESynergistic/additive cytotoxic effect of anti-EGFR
and anti-STAT agents
STAT3 has been associated with EGFR-independent activity
(Fernandes et al., 1999; Sriuranpong et al., 2003). Constitu-
tively activated STAT3 can be attributed to increased Src and
Jak activities (Garcia et al., 2001). Consistent with these re-
ports, STAT3 interacts with the cyclin D1 promoter in an EGF-
independent manner (Figure 2B). Furthermore, our results (Fig-
ure 5C) indicate that gefitinib was not completely effective in
inhibiting STAT3 activation as measured by p-STAT3. Thus, we
sought to investigate whether there was a therapeutic advan-
tage in combining agents targeting EGFR and STAT3. We found
that a combination of AG490 and AG1478 was more potent
than either inhibitor alone in killing A431 and MDA-MB-468
cells in both MTT and clonogenic assays (Figure 6A).
Next, we examined whether a therapeutic synergy or addi-
tive effect exists between agents targeting STAT3 and those
targeting EGFR by performing median-effect analyses as de-
scribed previously (Chou and Talalay, 1984). In these studies,
tumor cells were treated with AG490 and AG1478 for 24 hr and
with AG490 and gefitinib for 48 hr. Using the combination index
(CI) method/median-effect analysis, we determined the values
of CI for combination regimens. Synergism is indicated when
the derived CI value < 1.0, whereas CI = 1.0 reflects additive
effects, and CI > 1 represents antagonism. For MDA-MB-468
cells, the CIs for up to IC75 were below 1.0 for both AG490/
AG1478 combination regimens (Figure 6B, left). For A431 cells,
a synergistic effect between AG490 and AG1478 was seen
when a molar ratio of 1:2 (AG490/AG1478) was administered
(data not shown). When we replaced AG1478 with gefitinib, a
moderate synergy for up to IC50 was observed and an additive
effect, for above IC50 (Figure 6B, right). These effects were
observed when we administered AG490 and gefitinib with 2:1
and 4:1 in molar ratio. Collectively, these data indicate a thera-
peutic benefit for combining agents targeting EGFR and Jak/
STATs.
Reduction of the killing effect of anti-EGFR
and Jak2/STAT agents by increase
of cellular NO content
We then rationalized that NO would protect tumor cells from
the cytotoxic effect of AG490 and AG1478 if the iNOS/NO
pathway is indeed an important downstream player in the mito-
genic EGFR/STAT3 pathway. We also hypothesized that reduc-
tion of iNOS activity and NO content would provide a growth
disadvantage to tumor cells if the proliferation of these cells is
indeed facilitated by NO. As indicated in Figure 6C (left), prein-
cubation of the tumor cells for 30 min with a slow-releasing NO
donor, S-nitroso-N-acetylpenicillamine (SNAP), reduced the
killing effect of AG490/AG1478 (24 hr) from 96% to 57% in
A431 cells and from 79% to 42% in MDA-MB-468 cells. The
efficacy of SNAP in increasing NO levels is demonstrated in
Figure 6C (right). Moreover, MTT studies showed that specific
iNOS inhibitors (1400W and S-methylisothiourea, MIU) and NO
scavengers (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-
oxide, PTIO, and 2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imi-
dazoline-1-oxyl-3-oxide, c-PTIO) suppressed the growth of
MDA-MB-468 cells by approximately 42%–79% (Figure 6D,
left). More profound cell death was observed in treated cells
when clonogenic growth was measured (Figure 6D, right). Con-
sistently, SNAP pretreatment compromised the growth-sup-CANCER CELL : JUNE 2005pressing effect of 1400W (Figure 6E). Collectively, these data
suggest that NO facilitates the proliferation of tumor cells and
protects profound cell death resulting from suppression of the
EGFR/Jak/STATs and iNOS pathways by chemical inhibitors.
Positive correlation between levels of nuclear EGFR/
STAT3 and iNOS in primary breast carcinomas
We established, thus far, a positive regulatory role for nuclear
EGFR and STAT3 in iNOS expression in the cell culture system.
We next examined whether such regulation exists in primary
human tumors. Using immunohistochemical staining analysis,
we analyzed a cohort of 111 human breast carcinomas, pre-
viously analyzed for EGFR (Lo et al., 2005), for the expression
of iNOS and correlated iNOS expression with levels of EGFR.
A positive correlation was found between levels of nuclear
EGFR and iNOS (Figure 7A). EGFR in the nonnuclear compart-
ment, cytoplasm, and membrane, however, did not signifi-
cantly correlate with iNOS expression. In contrast, we did not
find a correlation between levels of iNOS/EGFR and tumor
grades.
To further investigate a possible correlation between acti-
vated STAT3 and nuclear EGFR/iNOS in primary tumor tissues,
we selected 15 tumors of those that had stained negative for
both nuclear EGFR and iNOS and 15 of those that had stained
positive for both markers, and we subjected them to immuno-
histochemical staining for p-STAT3 (Y705), the activated
nuclear form. Importantly, we found a significant positive corre-
lation between levels of p-STAT3 and expression of nuclear
EGFR and iNOS (Figure 7B). Representative tumors are shown
in Figure 7B (top): the tumor in the upper panel stained nega-
tive for nuclear EGFR (left), p-STAT3 (Y705, middle), and iNOS
(right) and that in the lower panel stained positive for all three
markers. Chi-square analysis showed a positive correlation be-
tween nuclear p-STAT3 level and nuclear EGFR/iNOS expres-
sion (p = 0.025); tumors with nuclear p-STAT3 expression
R20% were considered to have constitutively activated STAT3
(Hsiao et al., 2003; Khoury et al., 2003). As some reports con-
sider p-STAT3 expression R50% to be strong/constitutive ex-
pression (Masuda et al., 2002), we thus regrouped the cohort
into <50% andR50%, and the analysis showed that 40% (6/15)
and 80% (12/15) of the nuclear EGFR/iNOS-negative and -posi-
tive tumors, respectively, contained constitutively activated
STAT3. The difference was statistically significant (p = 0.005).
Furthermore, we found a lack of correlation between nonnu-
clear and nuclear levels of EGFR (Figure 7C), which supports
the concept that nuclear and nonnuclear EGFR pathways may
lead to different cellular targets.
We further examined whether iNOS expression correlated
with survival rate in this cohort. Interestingly, patients with me-
dium/high iNOS in their tumors were found to have a worse
survival rate compared to those with no/low expression (Figure
7D). For the classification of iNOS levels, we followed the sys-
tem that was reported previously (Ekmekcioglu et al., 2000;
Vakkala et al., 2000). Patients with tumors containing medium/
high iNOS levels constituted approximately 57.6% (64/111) of
the cohort with 43.5 ± 15.6 survival months, whereas those
with no/low iNOS contents, 42.4% (47/111), survived 53.5 ±
10.9 months. Together, these data indicate that the levels of
EGFR and STAT3 in tumor nuclei correlate with the level of
iNOS in human breast carcinomas, and iNOS may serve as a
prognostic indicator for patients with breast cancer.583
A R T I C L EFigure 6. Cytotoxic effect of agents targeting EGFR, Jak2/STATs, and iNOS/NO pathways
Means ± SD (error bars) were derived from at least three independent experiments.
A: Increased cell-killing effect when both EGFR and Jak2/STATs activities were inhibited. Left: MTT assay. Right: clonogenic growth assay.
B: A therapeutic advantage with combined targeting of Jak2/STATs and EGFR.
C: NO protects tumor cells from AG490/AG1478-induced cell death. Growth of tumor cells was measured using MTT assay following treatment of SNAP
(500 M), AG490/AG1478 (10/20 M), or all three agents for 24 hr (left). Total nitrate/nitrite content of SNAP-treated cells was measured (right).
D: Reduction of tumor cell growth by iNOS/NO inhibitors. Following treatment of 1400W (500 M), MIU (1 mM), PTIO (10 M), and cPTIO (500 M) for 48 hr,
MDA-MB-468 cell growth was determined using MTT (left) and clonogenic growth (right) assays.
E: SNAP compromises the growth-suppressing effect of 1400W. MTT assay was performed after a 48 hr treatment.584 CANCER CELL : JUNE 2005
A R T I C L EFigure 7. Positive correlation between levels of
nuclear EGFR and iNOS in breast tumors and the
level of iNOS as a prognostic marker for breast
cancer patients
Levels of iNOS and p-STAT3 (Y705) in a cohort of
primary breast carcinoma specimens, for which
EGFR levels had been evaluated previously (Lo
et al., 2005), were determined using immuno-
chemical staining.
A: Positive correlation between nuclear EGFR
and iNOS, calculated using the Pearson χ2 test.
B: Correlation between the level of p-STAT3 and
the levels of nuclear EGFR and of iNOS. A repre-
sentative tumor that is negative for nuclear
EGFR, p-STAT3, and iNOS (top) and a represen-
tative tumor that is positive for all three signals
(middle) are shown. Bottom panel: χ2 analysis of
30 tumors stained for all three proteins. Tumors
with nuclear p-STAT3 R 20% were considered to
exhibit strong/constitutive staining.
C: Lack of correlation between levels of nuclear
and nonnuclear EGFR by regression analysis.
D: High levels of iNOS as a prognostic indicator
for poor survival. Kaplan-Meier survival analysis
and the log-rank test were performed to corre-
late the levels of iNOS, no/low (0%–25%) and
medium/high (R26%), with overall patient sur-
vival.Discussion
The findings of the current study advance our knowledge of
the functions of nuclear EGFR. First, we showed that STAT3
physically associates and colocalizes with EGFR in the cell nu-
cleus following EGF stimulation. This finding is of particular im-
portance in understanding how nuclear EGFR, which lacks a
putative DNA binding domain, regulates gene expression. Sec-
ond, we found that the EGFR/STAT3 complex interacts with the
human iNOS promoter and activates iNOS gene expression. As
the role of EGF/EGFR in iNOS/NO pathway remains elusive,
our findings demonstrate crosstalk between two cellular path-
ways, both involved in tumorigenesis and various processes
of tumor progression. Third, via the structural and functional
characterization of the iNOS promoter, we identified two re-CANCER CELL : JUNE 2005gions within the iNOS promoter that contain binding elements
for both EGFR and STAT3. Fourth, we observed in primary hu-
man breast carcinomas that expression of nuclear EGFR posi-
tively correlates with that of iNOS. We also found a significant
inverse correlation between iNOS expression and patient sur-
vival in the cohort. Finally, we provided evidence showing the
therapeutic advantage of suppressing tumor cell growth by
combining agents targeting EGFR and Jak2/STATs.
Although it remains elusive whether EGF regulates expres-
sion of iNOS (Gallo et al., 2002; Liu and Neufeld, 2003; Salz-
man et al., 1996; Wang et al., 1999), our results provide conclu-
sive evidence showing that the EGF/EGFR/STAT3 growth
factor pathway activates iNOS gene expression and subse-
quent NO synthesis in human tumor cells. This finding is be-
lieved to be of particular importance, especially in view of a585
A R T I C L Enew mode of transcriptional regulation that involves a nuclear
oncogenic RTK, EGFR, and an oncogenic transcription factor,
STAT3. This transcriptional machinery may potentially occur in
other cell signaling modules composed of cell-surface recep-
tors and their associating transcription factors that shuttle be-
tween the cell surface and the nucleus. In this context, other
cell-surface receptors that are capable of interacting with tran-
scription factors and of translocating into the nucleus may uti-
lize similar mechanisms to regulate gene expression. The
known receptor/transcription factor modules include IFNγR/
STAT1, IL receptors/STATs, and TGF-βRI/Smads (Darnell et al.,
1994; Larkin et al., 2000; Reguly and Wrana, 2003; Zwaagstra
et al., 2000). Interestingly, IFNγR subunit I, receptors to IL-1
and IL-5, and the TGF-β type I receptor have also been found
in the nucleus (Bader and Weitzerbin, 1994; Curtis et al., 1990;
Jans et al., 1997; Larkin et al., 2000; Subramaniam and John-
son, 2002; Zwaagstra et al., 2000). Similar to the EGF/EGFR
pathway, nuclear translocalization of IFN-γR occurs following
IFN-γ stimulation (Bader and Weitzerbin, 1994; Larkin et al.,
2000; Subramaniam and Johnson, 2002). IFN-γR subunit I co-
localizes with STAT1α in the nucleus following IFN-γ treatment
(Larkin et al., 2000). The primary nuclear function of IFN-γ has
been shown to be involved in the enhancement of STAT1α
transcriptional activity (Subramaniam et al., 2001). Taken to-
gether, our study certainly prompts an urgent need to inves-
tigate whether these receptor/transcription factor modules
indeed have a direct physical interaction in the nuclear com-
partment leading to transcriptional regulation, as seen with
EGFR/STAT3.
Our analyses of the cyclin D1 and c-fos promoters indicate
that the EGFR/STAT3 complex may not be involved substan-
tially in their activation, as the sequential ChIP studies did not
detect an association of EGFR and STAT3 in the same DNA
regions on these promoters (Figure 2C). However, the ChIP
analysis indicates that EGFR and STAT3 individually associate
with both promoters (Figure 2B). Together, the results suggest
that EGFR and STAT3 do not form a complex while binding to
these promoters. The current study suggests that the EGFR-
induced activation of STAT3 is more complicated than thought
previously. In addition to the traditional pathway in which EGFR
activates STAT3 and activated STAT3, in turn, translocates into
the nucleus to turn on gene expression, another mode of regu-
lation could be derived from the EGFR/STAT3 complex, which
coregulates transcription of genes such as the iNOS. These
two modes of regulation may not be mutually exclusive and
may be responsible for the activation of different genes (e.g.,
iNOS and cyclin D1). It is not yet clear how a gene promoter
can distinguish regulation by STAT3, nuclear EGFR, and the
EGFR/STAT3 complex. Several factors might contribute to this.
For instance, close proximity of EGFR and STAT3 binding sites
might be critical to allow formation of the EGFR/STAT3 com-
plex (c-fos might not belong to this class). Alternatively, the
location of EGFR and STAT3 on the same face of the DNA helix
might be important for EGFR/STAT3 complex formation. In the
case of the cyclin D1 promoter, STAT3 binding is constitutively
activated and not responsive to EGF stimulation. Structural
signatures/requirements for EGFR/STAT3-targeted promoters,
such as the nucleotide sequences and the distance between
the ATRS and STAT3 binding sites, will require further extensive
studies to provide more detailed definitions.
Our results (Figure 5C) indicate insufficient suppression of586STAT3 activity by the anti-EGFR agent gefitinib. Skin biopsy
from gefitinib-treated patients was found to contain insufficient
suppression of STAT3 activity despite complete inhibition of
EGFR activity (Albanell et al., 2001). In addition, STAT3 is con-
stitutively activated in many human cancers and can take place
in both EGFR-dependent and -independent fashions (Fernan-
des et al., 1999; Sriuranpong et al., 2003). Constitutive activity
of STAT3-activating kinases, Src and Jaks, contributes to the
EGF-independent activation of STAT3 in breast cancers (Garcia
et al., 2001). We therefore reasoned that combined usage of
agents targeting EGFR and Jak/STATs would result in a better
therapeutic effect. Our cytotoxicity results indeed suggest a
therapeutic advantage for the combined use of AG490 and
AG1478, as well as AG490 and gefitinib, compared to the use
of single agents in MDA-MB-468 cells. In support of our find-
ing, a recent report showed a better cytotoxic effect in A431
cells when AG490 and AG1478 were used in combination
compared to treatment with either agent alone (Dowlati et al.,
2004).
A recent study (Bild et al., 2002) reported the cotransit of
EGF and STAT3 from the cell surface to the perinuclear region
via endosomes. Inhibition of endocytosis blocked this move-
ment and subsequent STAT3 nuclear activity. Although the
presence of EGFR in the complex was not investigated, EGF
presumably remains bound to EGFR, which implies that EGFR
may cotransit with STAT3 from the cytoplasmic membrane to
the perinuclear region and subsequently enter the cell nucleus.
Our data shown in Figure 5D certainly do not exclude this ex-
citing possibility, but only suggest that STAT3 nuclear translo-
cation can occur independently of the nuclear transport of
EGFR, which requires the putative NLS. Although we do not
have evidence showing that the EGFR-pNLS mutant is not de-
fective in EGF-activated endocytosis, based on the study by
Bild et al. (Bild et al., 2002) and our current study showing that
EGFR-pNLS mutant undergoes autophosphorylation (Figure
5F), this mutant may retain the wild-type ability to undergo
EGF-activated endocytosis and allow STAT3 to enter the cyto-
plasm, perinuclear region, and the nucleus. Further investiga-
tion is needed to examine this possibility.
In summary, the identified transcriptional complex consisting
of EGFR and STAT3 may potentially represent a class of tran-
scription factors that functionally interact at both cytoplasmic
and nuclear levels, resulting in a direct transduction of extracel-
lular signals from the cell surface to the nucleus. As iNOS
serves as a direct target of the identified EGFR/STAT3 tran-
scriptional complex, the deregulated iNOS/NO pathway may,
in part, contribute to the malignant biology of tumor cells with
high levels of nuclear EGFR and STAT3.
Experimental procedures
Cell lines and cell culture
A431 human epidermoid carcinoma cells, MDA-MB-468 human breast car-
cinoma cells, EGFR-null Chinese Hamster Ovary (CHO) cells, HaCaT human
keratinocytes, and Hela human cervical carcinoma cells were obtained from
ATCC. CHO-NEO, CHO-EGFR, and CHO-EGFR-pNLS stable cells were de-
rived from the parental CHO cells. All cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum,
except that, in addition, CHO-NEO, CHO-EGFR, and CHO-EGFR-pNLS
stable lines were supplemented with 1 mg/ml G418.CANCER CELL : JUNE 2005
A R T I C L ETransmission electron microscopy
Serum-starved MDA-MB-468 cells were treated with 100 ng/ml EGF for 30
min and subjected to EM analysis. Briefly, following incubation with both
mouse and rabbit IgGs, cell sections were treated with specific monoclonal
EGFR Ab (Zymed Laboratories) and polyclonal STAT3 Ab (C-20; Santa Cruz
Biotechnology, Inc.). Cells were then incubated with gold particle (5 or 15
nm) labeled goat anti-mouse and anti-rabbit secondary Abs (Amersham
Biosciences, USA), diluted 1:20 for 45 min. Sections were washed, stained
with uranyl acetate for 2 min and Reynolds’s lead citrate for 1 min, and
examined in a Jeol 1200EX microscope.
Generation of EGFR-pNLS mutant-expressing vector and stable cells
To generate the pNLS mutant of EGFR, specific alanine mutations were
constructed by site-directed mutagenesis, using the wild-type EGFR cDNA
template that was cloned into the pBluescript phagemid (Stratagene). The
selection primer, 5#-ATCGATACCGTCGACCTCGCCGCGGGGCCCGGTAC
CCAATTC-3#, was designed to replace the XhoI site in the pBluescript
phagemid with a Sacll site. The mutagenic primer, 5#-CCTTCACACATAC
TGCGGCGCTGGATCCACAGG-3#, replaced the putative NLS (645RRR647)
with alanine residues (645AAA647). Positive clones were obtained and their
nucleotide sequences confirmed and they were designated pBS-EGFR-
pNLS. The wild-type EGFR and EGFR-pNLS mutant cDNAs were then sub-
cloned into XbaI and HindIII sites of pcDNA3.1 (Invitrogen) and positive
clones designated pcDNA3.1-EGFR and pcDNA3.1-EGFR-pNLS, respec-
tively. The authenticity of both constructs was confirmed via nucleotide se-
quencing. To generate cells stably expressing the wild-type EGFR and
EGFR-pNLS mutant, pcDNA3.1-EGFR and pcDNA3.1-EGFR-pNLS, re-
spectively, were transfected into the parental EGFR-null CHO cells. The
empty vector pcDNA3.1 was transduced into CHO cells as a negative con-
trol. Following a 1 month selection period using 1 mg/ml G418, approxi-
mately 40 clones were selected and examined for levels of EGFR using WB
analysis. Stable cells expressing the empty vector, wild-type EGFR, and
EGFR-pNLS were designated CHO-NEO, CHO-EGFR, and CHO-EGFR-
pNLS, respectively.
Supplemental data
Supplemental Data include three figures, two tables, Supplemental Experi-
mental Procedures, and Supplemental References and can be found with
this article online at http://www.cancercell.org/cgi/content/full/7/6/575/DC1/.
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